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Radiotherapy can lead to both acute and late side effects, the form er occurring over a 
timescale of weeks and then subsiding. 
Late effects occur m onths or even years 
after cessation of treatm ent and often 
show continuous progression with 
time. W ith conventionally fractionated 
radiotherapy, the late side effects 
usually lim it the dose.
There are clear differences between 
patients regarding side effects: 
some patients appear to tolerate the 
treatm ent well, while others develop 
severe symptoms. Radiotherapy 
dose schedules have therefore been 
designed on past experience so that no 
m ore than 5%-10% of patients develop 
such severe side effects.
The question that has occupied 
radiation oncologists and scientists for 
many years is: what is different about 
the patients who develop the severe 
side effects? If we knew this, these 
patients could be given alternative 
schedules, doses, or treatm ents in 
order to produce m ore tolerable 
effects. In addition, and perhaps more 
importantly, the rem aining majority 
of patients could be given a higher 
dose, leading to higher cure rates [1]. 
The question is therefore potentially 
im portant, bu t has n o t been an easy 
one to answer.
Can Lymphocyte Response Predict 
Patient Morbidity?
In a new study published in P LoS  
M edicine, J. Peter Svensson and 
colleagues present an intriguing 
attem pt to elucidate genetic factors 
involved in late radiation toxicity 
[2]. Their approach was to look 
at differences in gene expression 
in lymphocytes of patients treated 
for prostate cancer. They hoped to 
discriminate patients with severe late 
radiation complications following
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radiotherapy (“over-responders”
[OR]) from patients without such 
complications (“non-responders” 
[NR]). The OR group showed severe 
late complications of rectum  an d /o r
The question is: what 
is different about the 
patients who develop 
severe side effects?
bladder, tissues which are unavoidably 
included in the radiation field. Twenty- 
one over-responders and 17 non­
responders participated in the primary 
classification study. Twelve patients 
(6 ORs and 6 NRs) were used for 
independen t validation.
Peripheral blood lymphocytes 
from both  the NR and OR groups 
were stimulated to proliferate with 
phytohaem agglutinin for two days.
The lymphocytes were irradiated with
2 Gy (the standard daily radiotherapy 
dose) and then RNA was extracted 
24 hours later for m icroarray analysis. 
Changes in gene expression resulting 
from the ex vivo irradiation were 
found to correlate with OR and NR 
status, although the perform ance 
of the classifier was only m oderate 
(the classifier based on the radiation 
response of separate genes correctly 
classified 63% of the patients).
Better perform ance was achieved by 
considering sets of genes on specific 
functional pathways based on the Gene 
Ontology categories, including those 
for apoptosis, protein metabolism 
and ubiquitination, development, and 
stress signaling. Such gene sets were 
able to predict OR and NR status with 
an 83% accuracy. If validated, this 
would represent a step forward for the 
radiation oncologist.
Strengths and Weaknesses 
of the Study
There are two major strengths of this 
study. The first is the selection of a 
good num ber of over-responders (27)
from an initially large series (800) of 
patients treated in a single institute for 
prostate cancer. Identifying and then 
collecting material for analysis from 
this relatively homogeneously treated 
group is a valuable achievement. 
Second, the analysis of sets of 
functionally related genes, in addition 
to the usual approach of treating each 
gene separately, was clearly a step in 
the right direction, a trend now seen in 
many microarray studies.
Paradoxically, the num ber of patients 
in the study is also a weakness. The 
num ber of events (serious side effects) 
eventually found and used for the 
training series was no t large (21) and 
the validation population was small 
(6 ORs + 6 NRs). This was reflected 
in a m oderate perform ance on the 
validation group, eight of 12 being 
correctly predicted, no t significantly 
different from random  chance. As 
adm itted by the authors, part of this 
poor perform ance may have been due 
to slight differences in the handling 
of lymphocytes. Further studies are 
therefore required to see if these 
intriguing, preliminary results hold up. 
As with all microarray studies, finding
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a classifier in a training group is not 
difficult. Finding a robust predictor 
withstanding validation in independent 
trials has tu rned out to be a lot more 
challenging.
Why Lymphocytes?
If these results do hold up after further 
investigation, another question arises. 
The norm al tissues dam aged by 
radiation in this study were bladder 
and rectum . Some dose to these organs 
cannot be avoided, even by m odern 
conformal radiotherapy. The question 
is: why should gene expression in a 
lymphocyte predict what will happen 
in these different and complex tissues, 
comprising largely epithelial, stromal, 
and vascular cells? The assumption 
is that there are underlying genetic 
factors governing the response of most 
or all tissues in the body to radiation. 
This is n o t immediately obvious. 
Radiation pathogenesis in such tissues 
depends on a num ber of factors, 
including damage to parenchymal cells 
and vasculature, and often involves 
various cytokines (e.g., TGF-beta) [3]. 
These factors will n o t be involved, or 
will only be involved to a lesser extent, 
in the response of lymphocytes.
In defense of Svensson and 
colleagues’ approach, at least 
two studies have shown that the 
extent of cytogenetic damage in 
lymphocytes irradiated ex vivo 
correlates with norm al tissue 
damage after radiotherapy [4,5].
Correlations of cytogenetic damage 
with gene expression would then 
support the present approach.
There is little inform ation on this, 
although it is logical to assume that 
intrinsic radiosensitivity differences 
will be reflected in expression or 
function of the many genes affecting 
radiosensitivity. Reiger and colleagues 
[6] showed that expression changes 
in lymphoblastoid lines derived 
from patients and irradiated ex vivo 
correlated with radiation-induced 
morbidity, although again the study was 
small (14 patients).
Questions and Future Directions
Tissue and vascular factors undoubtedly 
influence the pathogenesis of norm al 
tissue damage, and can vary between 
patients. Lymphocyte expression 
studies will n o t address these factors.
If lymphocyte gene expression indeed 
turns out to be highly predictive in 
further investigations, it would imply 
that such tissue-related factors play only 
a m inor role, which would represent a 
surprising and interesting finding.
More probably, tissue factors, maybe 
organ specific, will be found to play a 
role, and will eventually also need to 
be taken into account in any predictive 
test. Assuming genetic factors 
determ ine norm al tissue damage, 
these could indeed be analyzed in 
lymphocytes, bu t at the DNA level. 
Single nucleotide polymorphisms, for 
example, have already shown some
promise in predicting norm al tissue 
morbidity [7]. Using lymphocytes for 
this purpose may be m ore fruitful than 
analyzing gene expression, but time will 
tell. The statistical power of Svensson 
and colleagues’ study is too low to 
warrant unbridled optimism at present, 
although it will surely stimulate further 
investigations and hopefully lead to 
improvements in radiotherapy. ■
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